

## Variation in Erythromycin and Clindamycin Susceptibilities of *Streptococcus pneumoniae* by Four Test Methods

ELIZABETH L. FASOLA,<sup>1</sup> SARALEE BAJAKSOUZIAN,<sup>1</sup> PETER C. APPELBAUM,<sup>2</sup>  
AND MICHAEL R. JACOBS<sup>1\*</sup>

Departments of Pathology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio,<sup>1</sup>  
and Hershey Medical Center, Hershey, Pennsylvania<sup>2</sup>

Received 29 May 1996/Returned for modification 27 August 1996/Accepted 8 October 1996

**Susceptibilities of 124 strains of *Streptococcus pneumoniae* to erythromycin and clindamycin were determined by the National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method, with incubation for 20 to 24 h in ambient air and with modifications of this method by incubation for up to 48 h in air and CO<sub>2</sub>. Strains were also tested by agar dilution, E-test, and disk diffusion; good correlation was obtained with these methods, with clear separation into bimodal populations of susceptible and resistant strains. The broth microdilution method, however, using incubation in air for 24 h (NCCLS method), misclassified 4 of 92 erythromycin-resistant strains (1 as susceptible and 3 as intermediate) and 25 of 58 clindamycin-resistant strains (all as susceptible). With the exception of one strain with clindamycin, susceptible and resistant strains were correctly classified by the microdilution method with incubation in CO<sub>2</sub> for 24 h or in ambient air for 48 h. Disk diffusion, agar dilution, and E-test methods with incubation in 5% CO<sub>2</sub> are therefore reliable methods for susceptibility testing of pneumococci against these agents. However, the NCCLS microdilution method, which specifies incubation for 20 to 24 h in ambient air, produced significant very major errors (43%) with clindamycin. Modification of the microdilution method by incubation in 5% CO<sub>2</sub> or by extension of incubation time in ambient air to 48 h corrected these errors. Disk diffusion, however, was shown to be a simple, convenient, and reliable method for susceptibility testing of pneumococci to erythromycin and clindamycin and is suggested as the method of choice for these agents.**

*Streptococcus pneumoniae* is the most common causative organism of community-acquired pneumonia, bronchitis, otitis media, and sinusitis. Pathogens in these diseases are rarely identified due to lack of adequate clinical specimens, and antimicrobial therapy is usually chosen empirically. Erythromycin and other macrolides have been considered as belonging to one of the antibiotic groups of choice for treating many of these community-acquired infections because they are active against pneumococci and other pathogens commonly associated with these diseases (16). Macrolides are often the agents of choice for patients allergic to penicillin. However, erythromycin-resistant strains of *S. pneumoniae* have been isolated with increased frequency in several countries in Europe, as well as in Japan, Korea, Hong Kong, South Africa, and more recently also in the United States (1, 2, 4, 5, 8-12), and the choice of agents for empiric use needs to be reevaluated.

Erythromycin is a macrolide antibiotic which inhibits protein synthesis by binding to the 50S ribosomal subunit (19). Cross-resistance among macrolides, lincosamides, and streptogramin type B agents usually occurs in gram-positive organisms (11). Therefore, erythromycin-resistant strains of *S. pneumoniae* have usually been considered resistant to all other macrolides and lincosamides, including clindamycin, clarithromycin, and azithromycin (1, 7, 9). However, more recent reports have documented erythromycin-resistant *S. pneumoniae* strains in the United States that are susceptible to clindamycin (3, 15), and the same phenomenon has been reported for *S. pyogenes* in Finland (17).

While testing erythromycin and clindamycin against pneu-

mococci by broth microdilution using ambient air incubation for 20 to 24 h as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) for susceptibility testing of pneumococci (13), we observed many isolates that showed trailing endpoints after incubation, particularly with clindamycin, although this was also noted with some isolates with erythromycin. These observations prompted a study to compare methods for susceptibility testing of macrolides and lincosamides against pneumococci.

Four methods for susceptibility testing of *S. pneumoniae* with erythromycin and clindamycin were evaluated: broth microdilution MIC, agar dilution MIC, E-test MIC, and disk diffusion testing. Test variables used were incubation in ambient air compared to incubation in 5% CO<sub>2</sub> and extension of incubation time from 24 to 48 h.

(Presented in part at the 95th General Meeting of the American Society for Microbiology and at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy.)

### MATERIALS AND METHODS

**Strains.** One hundred and twenty-four selected strains of *S. pneumoniae* were chosen from our pneumococcal collection to represent as many countries, resistance patterns (other than resistance to macrolides), and serotypes as possible, with an emphasis on including as many erythromycin-resistant strains as possible. The final selection included 92 erythromycin-resistant strains with 32 erythromycin-susceptible strains chosen as controls. Strains were all clinical isolates recovered from various sources representing invasive and noninvasive strains, from the United States, Europe, Africa, Japan, and Korea.

**Susceptibility testing. Antimicrobial agents.** The following agents were used: penicillin G (Squibb Institute for Medical Research, Princeton, N.J.), erythromycin (Abbott Laboratories, North Chicago, Ill.), and clindamycin (Upjohn Co., Kalamazoo, Mich.).

**Quality control organisms.** *S. pneumoniae* ATCC 49619 was tested by all methods on each day of testing. Additional control strains included *Staphylococcus aureus* ATCC 29213 for broth microdilution and agar dilution testing and *S. aureus* ATCC 25923 for disk diffusion testing.

\* Corresponding author. Mailing address: Department of Pathology, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106. Phone: (216) 844-1828. Fax: (216) 844-5601.

**Broth microdilution MICs.** Microdilution trays were prepared in house using cation-supplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) with 5% lysed horse blood (Cleveland Scientific, Bath, Ohio). Erythromycin and clindamycin were tested at doubling dilutions from 0.03 to 32  $\mu\text{g/ml}$ . Inocula were prepared by suspending growth obtained from sheep blood agar plates that had been incubated for 20 to 24 h in 5%  $\text{CO}_2$ . Colonies were suspended in Mueller-Hinton broth to obtain a suspension equivalent to a 0.5 McFarland turbidity standard. The suspension was further diluted within 15 min to provide a final inoculum density of  $5 \times 10^5$  CFU/ml. Trays were inoculated in duplicate, with one being incubated aerobically as recommended by the NCCLS (13) and the other being incubated in 5%  $\text{CO}_2$ . MICs were read at 24 and 48 h. Trays were not stacked when incubated in the 5%  $\text{CO}_2$  atmosphere to allow adequate exposure of the tray to the atmospheric conditions. Inoculum size was checked by performing viable counts of inocula on random strains throughout the study for all test methods.

**Agar dilution MICs.** Agar dilution plates were made by adding antibiotic solutions to molten Mueller-Hinton agar (Difco) supplemented with 5% sheep blood. Penicillin was tested at doubling dilutions from 0.008 to 32  $\mu\text{g/ml}$ . Erythromycin and clindamycin were tested at doubling dilutions from 0.03 to 64  $\mu\text{g/ml}$ . A multipoint replicator (Craft Machine, Chester, Pa.) was used to inoculate duplicate sets of agar plates with 1  $\mu\text{l}$  of a suitably diluted organism suspension, prepared from suspensions equivalent to a 0.5 McFarland standard, to produce inocula of  $10^4$  CFU/spot. Plates were incubated aerobically and in 5%  $\text{CO}_2$ , and MICs were read at 24 and 48 h.

**E-test MICs.** Erythromycin and clindamycin E-test strips (AB Biodisk, Piscataway, N.Y.), calibrated to read MICs from 0.016 to 256  $\mu\text{g/ml}$ , were tested on 150-mm-diameter plates containing Mueller-Hinton agar supplemented with 5% sheep blood (Becton Dickinson Microbiology Systems, Cockeysville, Md.). Inocula were prepared as described above for the agar dilution. Plates were incubated in 5%  $\text{CO}_2$ , and MICs were read at 24 and 48 h.

**Disk diffusion.** Disk diffusion tests were performed using 150-mm-diameter plates containing Mueller-Hinton agar supplemented with 5% sheep blood agar and inocula were prepared as for the E-tests above according to NCCLS methods (14). Antibiotic disks (Becton Dickinson) tested were erythromycin (15- $\mu\text{g}$  disks), clindamycin (2- $\mu\text{g}$  disks), clarithromycin (15- $\mu\text{g}$  disks), and azithromycin (15- $\mu\text{g}$  disks). Plates were incubated in 5%  $\text{CO}_2$ , and zones of inhibition were read at 24 and 48 h.

**Interpretative criteria for susceptibility testing.** The MIC breakpoints published by NCCLS in M100-S6 of December 1995 (13) were used and were as follows: penicillin,  $\leq 0.06$   $\mu\text{g/ml}$ , susceptible, 0.1 to 1  $\mu\text{g/ml}$ , intermediate, and  $\geq 2$   $\mu\text{g/ml}$ , resistant; erythromycin and clindamycin,  $\leq 0.25$   $\mu\text{g/ml}$ , susceptible, 0.5  $\mu\text{g/ml}$ , intermediate, and  $\geq 1$   $\mu\text{g/ml}$ , resistant. The criteria used for interpretation of disk diffusion zones were also from NCCLS M100-S6 as follows: susceptible,  $\geq 21$  mm, and resistant,  $\leq 15$  mm for erythromycin and clarithromycin; susceptible,  $\geq 19$  mm, and resistant,  $\leq 15$  mm for clindamycin; and susceptible,  $\geq 18$  mm, and resistant,  $\leq 13$  mm for azithromycin.

**Induction of resistance.** To investigate the inducibility of clindamycin resistance in the presence of erythromycin, selected erythromycin-resistant isolates appearing susceptible to clindamycin were inoculated into tubes containing 2 ml of Mueller-Hinton broth supplemented with 5% lysed horse blood and 2  $\mu\text{g}$  of erythromycin per ml. The tubes were incubated at 35°C in  $\text{CO}_2$  for 4 h and then tested for induction of resistance by spot inoculation of 10  $\mu\text{l}$  onto a set of three blood agar plates containing erythromycin (1  $\mu\text{g/ml}$ ), clindamycin (0.5  $\mu\text{g/ml}$ ), and erythromycin (2  $\mu\text{g/ml}$ ) plus clindamycin (0.5  $\mu\text{g/ml}$ ). The plates were incubated for 24 h in 5%  $\text{CO}_2$  and then inspected for growth.

## RESULTS

**Agar dilution.** Penicillin susceptibility testing was performed on the 124 pneumococcal strains and showed that 28 strains were susceptible (MICs, 0.015 to 0.06  $\mu\text{g/ml}$ ), 18 were intermediate (MICs, 0.12 to 0.5  $\mu\text{g/ml}$ ), and 78 were resistant (MICs, 2 to 8  $\mu\text{g/ml}$ ). Erythromycin-resistant strains were distributed in all groups, with 16 being in the penicillin-susceptible group, 18 in the penicillin-intermediate group, and 58 in the penicillin-resistant group (Table 1). Distribution of MICs of erythromycin and clindamycin with incubation in air and  $\text{CO}_2$  for 24 h is shown in Fig. 1 and 2.

For erythromycin and clindamycin, agar dilution results correlated well with E-test and disk diffusion results (Tables 2 and 3). All erythromycin-resistant strains were classified as resistant to erythromycin by agar dilution with incubation in either air or  $\text{CO}_2$ . Of 92 strains classified as erythromycin resistant, erythromycin MICs were  $\geq 32$   $\mu\text{g/ml}$  for 51 strains with incubation in air and for 70 strains with incubation in  $\text{CO}_2$  (Fig. 1). All erythromycin-susceptible strains were classified as susceptible to erythromycin and clindamycin regardless of whether

TABLE 1. Distribution of *S. pneumoniae* strains according to their susceptibilities to erythromycin, clindamycin, and penicillin

Penicillin category	No. of strains with the following resistance phenotype:		
	Erythromycin susceptible, clindamycin susceptible	Erythromycin resistant, clindamycin susceptible	Erythromycin resistant, clindamycin resistant
Susceptible	11	6	10
Intermediate	1	7	11
Resistant	20	21	37
All strains	32	34	58

they were tested in ambient air or  $\text{CO}_2$  (Fig. 1). The MIC at which 90% of strains are inhibited ( $\text{MIC}_{90}$ ) for erythromycin in this susceptible group using incubation in air for 24 h was  $\leq 0.03$   $\mu\text{g/ml}$  and was 0.06  $\mu\text{g/ml}$  with incubation in  $\text{CO}_2$ . Among the 58 clindamycin-resistant strains, 2 strains were incorrectly classified as susceptible by agar dilution using incubation in air (MICs of 0.03 and 0.06  $\mu\text{g/ml}$ ), and this was also true for 1 strain with incubation in  $\text{CO}_2$  (MIC of 0.25  $\mu\text{g/ml}$ ) (Fig. 2). The  $\text{MIC}_{90}$  of clindamycin was 0.06  $\mu\text{g/ml}$  with incubation in air and 0.12  $\mu\text{g/ml}$  with incubation in  $\text{CO}_2$  (Table 3).



**Broth microdilution.** Initially, it appeared that 25 erythromycin-resistant strains had inducible clindamycin resistance when tested by microdilution in ambient air, as these strains showed trailing endpoints in the clindamycin wells at 24 h and MICs were higher at 48 h. However, when these isolates were tested for susceptibility to clindamycin by the other three methods, such isolates were shown to be highly clindamycin resistant after 24 h of incubation (Tables 2 and 3). Furthermore, although these isolates did not require  $\text{CO}_2$  for growth (as evidenced by good growth in the control wells), all but one isolate were detected as resistant to clindamycin in 24 h by broth microdilution using  $\text{CO}_2$  incubation, and that isolate became resistant at 48 h in  $\text{CO}_2$ . For clindamycin, therefore, broth microdilution with incubation in air produced 33 very major errors at 24 h and 13 at 48 h, with the  $\text{MIC}_{50}$  for clindamycin-resistant strains increasing from 1  $\mu\text{g/ml}$  at 24 h to  $\geq 32$   $\mu\text{g/ml}$  at 48 h.

The effect of  $\text{CO}_2$  incubation on susceptibility testing of erythromycin by broth microdilution was not as marked as it was for clindamycin (Fig. 1). All erythromycin-resistant strains were classified as resistant by this method using incubation in 5%  $\text{CO}_2$ , while one was susceptible and three were intermediate at 24 h in air; all were correctly classified at 48 h in both atmospheres.

**Disk diffusion.** Most of the resistant isolates showed no inhibition zones around the disks or had inhibition zones far smaller than the breakpoints, while susceptible strains had zones well above the breakpoints at 24 h (Fig. 3). For erythromycin- and clindamycin-susceptible isolates, the zones of inhibition were  $\geq 26$  and  $\geq 23$  mm, respectively. One isolate was classified as clindamycin resistant by disk diffusion and susceptible by agar dilution and E-test at 24 h (Table 2). The clindamycin MIC at 24 h for this isolate was 0.25  $\mu\text{g/ml}$  (the upper limit of susceptible), but there was no inhibition of growth around the clindamycin disk. This strain became resistant at 48 h by agar dilution and E-test. Disk diffusion therefore clearly differentiated erythromycin- and clindamycin-susceptible isolates from resistant isolates.

To evaluate cross-resistance with other members of the macrolide-azalide group in *S. pneumoniae*, clarithromycin and azithromycin were also tested by disk diffusion. All pneumo-

## a. Agar dilution incubated aerobically

b. Agar dilution incubated in CO<sub>2</sub>

## c. Broth microdilution incubated aerobically



d. Broth microdilution incubated in CO<sub>2</sub>

FIG. 1. Erythromycin MIC distribution in air and CO<sub>2</sub> by agar dilution and broth microdilution after incubation for 24 h for susceptible strains (hatched bars) and resistant strains (solid bars).

coccal isolates that were resistant to erythromycin were also resistant to clarithromycin and azithromycin (Fig. 3). For clarithromycin, zones of inhibition were  $\leq 16$  mm for resistant isolates and zones were  $\geq 26$  mm for susceptible isolates. Comparable zones for azithromycin were  $\leq 12$  mm for resistant strains and  $\geq 21$  mm for susceptible strains.



**E-test.** E-test results correlated well with the other methods, although MICs for susceptible strains tended to be one or two dilutions higher than those observed by agar and broth dilution methods (Table 3). The erythromycin MIC<sub>50</sub> and MIC<sub>90</sub> for erythromycin-susceptible strains were both 0.12  $\mu\text{g/ml}$ . The clindamycin MIC<sub>50</sub> for clindamycin-susceptible strains was 0.12 and the MIC<sub>90</sub> was 0.25  $\mu\text{g/ml}$ . MICs of both antimicrobial agents were  $\geq 256$   $\mu\text{g/ml}$  for most erythromycin- and clindamycin-resistant isolates by this method.

**Induction of resistance.** Clindamycin resistance could not be induced by preincubation with erythromycin (as described in Materials and Methods) in pneumococcal strains that were resistant to erythromycin but susceptible to clindamycin, suggesting that these strains were truly susceptible to clindamycin.

**pH effect of incubation in CO<sub>2</sub>.** The effect of erythromycin and clindamycin on the pH of the media used and the effect of incubation in air versus CO<sub>2</sub> were determined. The pH of the

agar and broth media used was between 7.2 and 7.4 before incubation and addition of antimicrobial agents. The pH of the agar medium with the highest concentration of erythromycin tested (64  $\mu\text{g/ml}$ ) was 7.3 on preparation, 7.5 after incubation of uninoculated medium for 24 h in air, and 7.3 after 48 h; corresponding values after incubation in CO<sub>2</sub> were 7.1 and 7.0. For clindamycin, pH of the medium was 7.3 on preparation, 7.5 and 7.4 after incubation in air for 24 and 48 h, respectively, and 7.1 and 7.0 after incubation in CO<sub>2</sub> for 24 and 48 h, respectively. Similar pH changes were found after incubation of the broth media containing 32  $\mu\text{g}$  of these agents per ml. pH of the media therefore was slightly higher than that for drug-free media at the highest concentrations of the agents, which are both alkaline and known to be less active as the pH is lowered. With incubation in air the pH rose slightly in 24 h but was close to the initial values after 48 h. However, with incubation in CO<sub>2</sub> pH fell to 7.1 after 24 h and 7.0 after 48 h, which could result in higher MICs due to lower activity of the agents at lower pHs. This effect was noted for susceptible strains, when modal MICs rose from  $\leq 0.03$   $\mu\text{g/ml}$  in air to 0.06  $\mu\text{g/ml}$  in CO<sub>2</sub> in 24 h for both agents. However, MICs for many resistant strains were considerably higher after incubation for 24 h in CO<sub>2</sub> or in air for 48 h than after incubation in air for 24 h (Fig.

## a. Agar dilution incubated aerobically

b. Agar dilution incubated in CO<sub>2</sub>

## c. Broth microdilution incubated aerobically



d. Broth microdilution incubated in CO<sub>2</sub>

FIG. 2. Clindamycin MIC distribution in air and CO<sub>2</sub> by agar dilution and broth microdilution after incubation for 24 h for susceptible strains (hatched bars) and resistant strains (solid bars).

1 and 2), which indicates that expression of resistance has a more profound effect on MICs than the pH changes.

## DISCUSSION

Erythromycin resistance among *S. pneumoniae* isolates has increased in the United States from approximately 0.2% in the

TABLE 2. Number of strains of *S. pneumoniae* susceptible to erythromycin and clindamycin according to test method, length of incubation, and incubation atmosphere<sup>a</sup>

Antibiotic	No. of strains susceptible by the following test method after incubation for 24/48 h <sup>b</sup> :			
	Agar dilution MIC (CO <sub>2</sub> )	Broth microdilution MIC (air)	E-test (CO <sub>2</sub> )	Disk diffusion (CO <sub>2</sub> )
Erythromycin	32/32	33 <sup>c</sup> /32	32/32	32/32
Clindamycin	67/66	91/71	67/66	66/66

<sup>a</sup> Of the 124 strains tested, 32 were susceptible to erythromycin and 66 were susceptible to clindamycin. Susceptible breakpoints for erythromycin were  $\leq 0.25$   $\mu\text{g/ml}$  for MICs and  $\geq 21$  mm for disk diffusion; corresponding breakpoints for clindamycin were  $\leq 0.25$   $\mu\text{g/ml}$  and  $\geq 19$  mm, respectively.

<sup>b</sup> The incubation atmosphere is in parentheses.

<sup>c</sup> MICs were in the intermediate range for three additional resistant strains.

late 1980s to 5% (9) and 15% (5) in some areas today. Several European countries have also reported an increase in erythromycin resistance, especially in France, where the resistance rate increased from 6% in 1970 to 25% in 1985 (2). In Spain, the macrolide resistance rate doubled in only 2 years, from 4 to 8.4% (2). Other countries, such as South Africa (9), have also reported an increased prevalence of erythromycin-resistant strains. In Hong Kong, the prevalence increased from 0% in 1983 to almost 40% in 1995 (8). An increase in erythromycin resistance has been also reported among group A streptococcal strains (6, 17), and this seems to correlate with increased clinical use of this agent in some areas (6), which could similarly play a role in the increase in macrolide resistance among pneumococci.

All erythromycin-resistant pneumococci reported to date have been cross-resistant to the macrolide and azalide agents, including clarithromycin and azithromycin (7, 10). Most of these erythromycin-resistant strains were also resistant to clindamycin, particularly those reported from South Africa and Europe. However, more recent reports described the detection of erythromycin-resistant pneumococcal isolates in the United States that were susceptible to clindamycin (3, 15). Similar findings have recently also been reported for group A strepto-

TABLE 3. MIC<sub>50</sub> and MIC<sub>90</sub> of erythromycin and clindamycin according to test method and atmosphere after incubation for 24 h


Group (no. of strains)	Result (µg/ml) in the following atmosphere by the following method:									
	Air					CO <sub>2</sub>				
	Microdilution		Agar dilution		Microdilution		Agar dilution		E-test	
	MIC <sub>50</sub>	MIC <sub>90</sub>	MIC <sub>50</sub>	MIC <sub>90</sub>	MIC <sub>50</sub>	MIC <sub>90</sub>	MIC <sub>50</sub>	MIC <sub>90</sub>	MIC <sub>50</sub>	MIC <sub>90</sub>
Erythromycin susceptible (32)	≤0.03	≤0.03	≤0.03	≤0.03	0.06	0.06	0.06	0.06	0.12	0.12
Erythromycin resistant (92)	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32
Clindamycin susceptible (66)	≤0.03	0.06	≤0.03	0.06	0.06	0.12	0.06	0.12	0.12	0.25
Clindamycin resistant (58)	1	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32

cocci in Finland (17). Our study has confirmed the presence of erythromycin-resistant clindamycin-susceptible strains in the United States and also detected this resistance pattern in strains from Japan, Korea, and Eastern Europe. The mechanism of resistance has recently been determined to be a macrolide efflux system which is functionally and genetically distinct from the macrolide efflux system found in coagulase-negative staphylococci (18).


Incubation of macrolides in CO<sub>2</sub> has been reported to raise

MICs due to acidification of the medium by CO<sub>2</sub> resulting in decreased macrolide activity (20). While this effect was seen in our study, MICs for susceptible strains remained in the susceptible range, while expression of resistance in resistant strains became much more marked, resulting in clear separation of susceptible and resistant populations. As this effect was seen with extension of incubation time in ambient air, the reason for this effect is postulated to be due to more rapid growth of strains in the presence of CO<sub>2</sub>, with earlier expres-


a. Erythromycin



b. Clindamycin



c. Azithromycin



d. Clarithromycin




FIG. 3. Distribution of zone diameters at 24 h by disk diffusion with susceptible strains (hatched bars) and resistant strains (solid bars). For clarity only 10 strains for which zone diameters were 6 mm are shown; actual numbers of strains are erythromycin, 67; clindamycin, 58; azithromycin, 71; and clarithromycin, 67.

sion or induction of macrolide resistance and not due to the rather small changes in pH noted.

In our study, many strains of erythromycin-resistant pneumococci appeared susceptible to clindamycin at 24 h by microdilution when incubated in ambient air but were resistant by the other three other methods which include incubation in CO<sub>2</sub> and by microdilution when incubated in CO<sub>2</sub>. The effect of CO<sub>2</sub> incubation on susceptibility testing of erythromycin was not as marked as it was for clindamycin, and most erythromycin-resistant isolates could be detected regardless of whether they were tested in ambient air or CO<sub>2</sub>. These findings are in agreement with those of a previous article (10). However, the NCCLS microdilution method, which specifies incubation in ambient air for 20 to 24 h, produced significant very major errors (43%; 25 of 58 strains) with clindamycin. Modification by incubation in CO<sub>2</sub> or extension of incubation time to 48 h corrected these errors. Disk diffusion, however, was the simplest and most convenient test method, with the same accuracy as or accuracy superior to agar dilution.

This study has documented problems associated with the NCCLS microdilution method for susceptibility testing of pneumococci, while showing the reliability of other methods. In addition, macrolide breakpoints recommended by the NCCLS should be modified to include intermediate strains as resistant, as such strains express higher levels of resistance with further incubation or with incubation in CO<sub>2</sub>.

#### ACKNOWLEDGMENTS

This work was supported in part by a grant from Pharmacia & Upjohn Inc., Kalamazoo, Mich.

We thank Joyce Sutcliffe, Pfizer Inc., Groton, Conn., for information on the mechanisms of macrolide resistance of streptococci.

#### REFERENCES

1. Appelbaum, P. C. 1992. Antimicrobial resistance in *Streptococcus pneumoniae*: an overview. *Clin. Infect. Dis.* **15**:77–83.
2. Baquero, F., J. Martínez-Beltrán, and E. Loza. 1991. A review of antibiotic resistance patterns of *Streptococcus pneumoniae* in Europe. *J. Antimicrob. Chemother.* **28**(Suppl. C):31–38.
3. Block, S. L., C. J. Harrison, J. A. Hedrick, R. D. Tyler, R. A. Smith, E. Keegan, and S. A. Chartrand. 1995. Penicillin-resistant *Streptococcus pneumoniae* in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. *Pediatr. Infect. Dis. J.* **14**:751–759.
4. Geslin, P., A. Buu-Hoi, A. Frémaux, and J. F. Acar. 1992. Antimicrobial resistance in *Streptococcus pneumoniae*: an epidemiological survey in France, 1970–1990. *Clin. Infect. Dis.* **15**:95–98.
5. Hofmann, J., M. S. Cetron, M. M. Farley, W. S. Baughman, R. R. Facklam, J. A. Elliot, K. A. Deaver, and R. F. Breiman. 1995. The prevalence of drug resistant *Streptococcus pneumoniae* in Atlanta. *N. Engl. J. Med.* **333**:481–486.
6. Hsueh, P. R., H. M. Chen, A. H. Huang, and J. J. Wu. 1995. Decreased activity against *Streptococcus pyogenes* in Taiwan. *Antimicrob. Agents Chemother.* **39**:2239–2242.
7. Jacobs, M. R., and P. C. Appelbaum. 1995. Antibiotic-resistant pneumococci. *Rev. Med. Microbiol.* **6**:77–93.
8. Kam, K. M., K. Y. Luey, S. M. Fung, P. P. Yiu, T. J. Harden, and M. M. Cheung. 1995. Emergence of multiple-antibiotic-resistant *Streptococcus pneumoniae* in Hong Kong. *Antimicrob. Agents Chemother.* **39**:2667–2670.
9. Klugman, K. P. 1990. Pneumococcal resistance to antibiotics. *Clin. Microbiol. Rev.* **3**:171–196.
10. Lonks, J. R., and A. A. Medeiros. 1993. High rate of erythromycin and clarithromycin resistance among *Streptococcus pneumoniae* isolates from blood cultures from Providence, R.I. *Antimicrob. Agents Chemother.* **37**:1742–1745.
11. Lonks, J. R., and A. A. Medeiros. 1994. Emergence of erythromycin-resistant *Streptococcus pneumoniae*. *Infect. Med.* **11**:415–418, 423–424.
12. Marton, A., M. Gulyas, R. Munoz, and A. Tomasz. 1991. Extremely high incidence of antibiotic resistance in clinical isolates of *Streptococcus pneumoniae* in Hungary. *J. Infect. Dis.* **163**:542–548.
13. National Committee for Clinical Laboratory Standards. 1995. Performance standards for antimicrobial susceptibility testing: sixth informational supplement. M100-S6. National Committee for Clinical Laboratory Standards, Villanova, Pa.
14. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial disk susceptibility test, 5th ed. Approved standard NCCLS document M2-A5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
15. Nelson, C. T., E. O. Mason, and S. L. Kaplan. 1994. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant *Streptococcus pneumoniae*: implications for treatment. *Pediatr. Infect. Dis. J.* **13**:585–589.
16. Pomilla, P. V., and R. B. Brown. 1994. Outpatient treatment of community-acquired pneumonia in adults. *Arch. Intern. Med.* **154**:1793–1802.
17. Seppala, H., A. Nissinen, Q. Yu, and P. Huovinen. 1993. Three different phenotypes of erythromycin-resistant *Streptococcus pyogenes* in Finland. *J. Antimicrob. Chemother.* **32**:885–891.
18. Sutcliffe, J., A. Tait-Kamradt, and J. Wondrack. 1996. *Streptococcus pneumoniae* and *Streptococcus pyogenes* resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. *Antimicrob. Agents Chemother.* **40**:1817–1824.
19. Weisblum, B. 1995. Insights into erythromycin action from studies of its activity as inducer of resistance. *Antimicrob. Agents Chemother.* **39**:797–805.
20. Woods, G. L., and J. A. Washington. 1995. Antibacterial susceptibility tests: dilution and disk diffusion methods, p. 1327. *In* P. R. Murray, E. J. Baron, M. A. Tenover, F. C. Tenover, and R. H. Tenover (ed.), *Manual of clinical microbiology*. American Society for Microbiology, Washington, D.C.